Endothelin and its suspected role in the pathogenesis and possible treatment of glaucoma

Yochai Z. Shoshani, Alon Harris, Mohammadali Mohajel Shoja, Deepam Rusia, Brent Siesky, Yoel Arieli, Barbara Wirostko

Research output: Contribution to journalReview article

33 Citations (Scopus)

Abstract

Purpose: To review the role of endothelin in intraocular pressure control, its effect on the trabecular meshwork (TM) and the outflow facility, effect on ocular blood flow and vascular regulation and the potential role of endothelin-1 (ET-1) antagonism in the therapeutic paradigm of glaucoma. Methods: A thorough review of the medical literature and a meta-analysis on the level of ET-1 in OAG patients in an attempt to demonstrate the evolving importance of endothelin in glaucoma. Results: ET-1 has been identified in the plasma in concentrations that are markedly increased in a number of systemic as well as ocular pathologies such as glaucoma where underlying vascular dysfunction and pathology play a role. It has been shown that ET-1 induces human TM cell contraction in culture and that it can affect the outflow facility. Evidence indicates that systemic ET-1 regulatory mechanisms and vascular responses to it are also altered in glaucoma. Recently, several endothelin antagonists have been shown to have a potential role in glaucoma therapy. In our meta-analysis, only patients with normal tension glaucoma (NTG) (as opposed to patients with high tension glaucoma (HTG)) had significantly higher plasma ET-1 levels compared to non-glaucomatous control. High tension glaucomaHTG patients had significant higher levels of ET-1 in the aqueous humor. Conclusions: The potential role of ET-1 antagonism in the therapeutic paradigm of glaucoma is an exciting possible new approach in the treatment of OAG patients. In NTG, ET-1 may have both a local and systemic component of vascular dysregulation, while whereas in HTG, the role of ET-1 may be dominantly localized to ocular tissue.

Original languageEnglish (US)
Pages (from-to)1-11
Number of pages11
JournalCurrent Eye Research
Volume37
Issue number1
DOIs
StatePublished - Jan 1 2012
Externally publishedYes

Fingerprint

Endothelins
Endothelin-1
Glaucoma
Blood Vessels
Low Tension Glaucoma
Trabecular Meshwork
Therapeutics
Meta-Analysis
Pathology
Aqueous Humor
Intraocular Pressure

Keywords

  • Endothelin
  • Glaucoma
  • Ocular blood flow
  • Treatment
  • Vascular dysregulation

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Shoshani, Y. Z., Harris, A., Mohajel Shoja, M., Rusia, D., Siesky, B., Arieli, Y., & Wirostko, B. (2012). Endothelin and its suspected role in the pathogenesis and possible treatment of glaucoma. Current Eye Research, 37(1), 1-11. https://doi.org/10.3109/02713683.2011.622849

Endothelin and its suspected role in the pathogenesis and possible treatment of glaucoma. / Shoshani, Yochai Z.; Harris, Alon; Mohajel Shoja, Mohammadali; Rusia, Deepam; Siesky, Brent; Arieli, Yoel; Wirostko, Barbara.

In: Current Eye Research, Vol. 37, No. 1, 01.01.2012, p. 1-11.

Research output: Contribution to journalReview article

Shoshani, YZ, Harris, A, Mohajel Shoja, M, Rusia, D, Siesky, B, Arieli, Y & Wirostko, B 2012, 'Endothelin and its suspected role in the pathogenesis and possible treatment of glaucoma', Current Eye Research, vol. 37, no. 1, pp. 1-11. https://doi.org/10.3109/02713683.2011.622849
Shoshani YZ, Harris A, Mohajel Shoja M, Rusia D, Siesky B, Arieli Y et al. Endothelin and its suspected role in the pathogenesis and possible treatment of glaucoma. Current Eye Research. 2012 Jan 1;37(1):1-11. https://doi.org/10.3109/02713683.2011.622849
Shoshani, Yochai Z. ; Harris, Alon ; Mohajel Shoja, Mohammadali ; Rusia, Deepam ; Siesky, Brent ; Arieli, Yoel ; Wirostko, Barbara. / Endothelin and its suspected role in the pathogenesis and possible treatment of glaucoma. In: Current Eye Research. 2012 ; Vol. 37, No. 1. pp. 1-11.
@article{654edb6bd5a44f88a72d2ebc75284f4c,
title = "Endothelin and its suspected role in the pathogenesis and possible treatment of glaucoma",
abstract = "Purpose: To review the role of endothelin in intraocular pressure control, its effect on the trabecular meshwork (TM) and the outflow facility, effect on ocular blood flow and vascular regulation and the potential role of endothelin-1 (ET-1) antagonism in the therapeutic paradigm of glaucoma. Methods: A thorough review of the medical literature and a meta-analysis on the level of ET-1 in OAG patients in an attempt to demonstrate the evolving importance of endothelin in glaucoma. Results: ET-1 has been identified in the plasma in concentrations that are markedly increased in a number of systemic as well as ocular pathologies such as glaucoma where underlying vascular dysfunction and pathology play a role. It has been shown that ET-1 induces human TM cell contraction in culture and that it can affect the outflow facility. Evidence indicates that systemic ET-1 regulatory mechanisms and vascular responses to it are also altered in glaucoma. Recently, several endothelin antagonists have been shown to have a potential role in glaucoma therapy. In our meta-analysis, only patients with normal tension glaucoma (NTG) (as opposed to patients with high tension glaucoma (HTG)) had significantly higher plasma ET-1 levels compared to non-glaucomatous control. High tension glaucomaHTG patients had significant higher levels of ET-1 in the aqueous humor. Conclusions: The potential role of ET-1 antagonism in the therapeutic paradigm of glaucoma is an exciting possible new approach in the treatment of OAG patients. In NTG, ET-1 may have both a local and systemic component of vascular dysregulation, while whereas in HTG, the role of ET-1 may be dominantly localized to ocular tissue.",
keywords = "Endothelin, Glaucoma, Ocular blood flow, Treatment, Vascular dysregulation",
author = "Shoshani, {Yochai Z.} and Alon Harris and {Mohajel Shoja}, Mohammadali and Deepam Rusia and Brent Siesky and Yoel Arieli and Barbara Wirostko",
year = "2012",
month = "1",
day = "1",
doi = "10.3109/02713683.2011.622849",
language = "English (US)",
volume = "37",
pages = "1--11",
journal = "Current Eye Research",
issn = "0271-3683",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Endothelin and its suspected role in the pathogenesis and possible treatment of glaucoma

AU - Shoshani, Yochai Z.

AU - Harris, Alon

AU - Mohajel Shoja, Mohammadali

AU - Rusia, Deepam

AU - Siesky, Brent

AU - Arieli, Yoel

AU - Wirostko, Barbara

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Purpose: To review the role of endothelin in intraocular pressure control, its effect on the trabecular meshwork (TM) and the outflow facility, effect on ocular blood flow and vascular regulation and the potential role of endothelin-1 (ET-1) antagonism in the therapeutic paradigm of glaucoma. Methods: A thorough review of the medical literature and a meta-analysis on the level of ET-1 in OAG patients in an attempt to demonstrate the evolving importance of endothelin in glaucoma. Results: ET-1 has been identified in the plasma in concentrations that are markedly increased in a number of systemic as well as ocular pathologies such as glaucoma where underlying vascular dysfunction and pathology play a role. It has been shown that ET-1 induces human TM cell contraction in culture and that it can affect the outflow facility. Evidence indicates that systemic ET-1 regulatory mechanisms and vascular responses to it are also altered in glaucoma. Recently, several endothelin antagonists have been shown to have a potential role in glaucoma therapy. In our meta-analysis, only patients with normal tension glaucoma (NTG) (as opposed to patients with high tension glaucoma (HTG)) had significantly higher plasma ET-1 levels compared to non-glaucomatous control. High tension glaucomaHTG patients had significant higher levels of ET-1 in the aqueous humor. Conclusions: The potential role of ET-1 antagonism in the therapeutic paradigm of glaucoma is an exciting possible new approach in the treatment of OAG patients. In NTG, ET-1 may have both a local and systemic component of vascular dysregulation, while whereas in HTG, the role of ET-1 may be dominantly localized to ocular tissue.

AB - Purpose: To review the role of endothelin in intraocular pressure control, its effect on the trabecular meshwork (TM) and the outflow facility, effect on ocular blood flow and vascular regulation and the potential role of endothelin-1 (ET-1) antagonism in the therapeutic paradigm of glaucoma. Methods: A thorough review of the medical literature and a meta-analysis on the level of ET-1 in OAG patients in an attempt to demonstrate the evolving importance of endothelin in glaucoma. Results: ET-1 has been identified in the plasma in concentrations that are markedly increased in a number of systemic as well as ocular pathologies such as glaucoma where underlying vascular dysfunction and pathology play a role. It has been shown that ET-1 induces human TM cell contraction in culture and that it can affect the outflow facility. Evidence indicates that systemic ET-1 regulatory mechanisms and vascular responses to it are also altered in glaucoma. Recently, several endothelin antagonists have been shown to have a potential role in glaucoma therapy. In our meta-analysis, only patients with normal tension glaucoma (NTG) (as opposed to patients with high tension glaucoma (HTG)) had significantly higher plasma ET-1 levels compared to non-glaucomatous control. High tension glaucomaHTG patients had significant higher levels of ET-1 in the aqueous humor. Conclusions: The potential role of ET-1 antagonism in the therapeutic paradigm of glaucoma is an exciting possible new approach in the treatment of OAG patients. In NTG, ET-1 may have both a local and systemic component of vascular dysregulation, while whereas in HTG, the role of ET-1 may be dominantly localized to ocular tissue.

KW - Endothelin

KW - Glaucoma

KW - Ocular blood flow

KW - Treatment

KW - Vascular dysregulation

UR - http://www.scopus.com/inward/record.url?scp=83655191290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83655191290&partnerID=8YFLogxK

U2 - 10.3109/02713683.2011.622849

DO - 10.3109/02713683.2011.622849

M3 - Review article

VL - 37

SP - 1

EP - 11

JO - Current Eye Research

JF - Current Eye Research

SN - 0271-3683

IS - 1

ER -